<DOC>
	<DOCNO>NCT00681941</DOCNO>
	<brief_summary>Approximately 45 hyperphosphatemic CKD patient dialysis enter study approximately 20 site within Europe 5-10 Australia . The purpose study determine sevelamer carbonate tablet dose three time day ( TID ) effective treatment control serum phosphorous level hyperphosphatemic CKD patient dialysis . Total length participation approximately 14 week .</brief_summary>
	<brief_title>An Open Label Dose Titration Sevelamer Carbonate Tabs 3 Times Day Hyperphosphatemic CKD Patients Not On Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>A minimum 120 male female patient chronic kidney disease require dialysis screen participation study . Men woman 18 year age old If currently take phosphate binder ( ) , willing stop enter 2 week washout period Willing avoid intentional change diet fast diet Have follow central laboratory measurement : 1 . If phosphate binder , serum phosphorus measurement ≥ 5.5 mg/dL ( 1.76 mmol/L ) Screening ( Visit1 ) . 2 . If take phosphate binder ( ) screening , serum phosphorus measurement ≥ 5.5 mg/dL ( 1.76 mmol/L ) twoweek washout period Visit 1a ( Day 0 ) . At Screening ( Visit 1 ) , follow central laboratory measurement : 1 . 25hydroxyvitamin D ≥ 10 ng/mL 2. iPTH ≤ 800 pg/mL Willing able take sevelamer carbonate alone phosphate binder duration study Willing able maintain screening dose lipid medication , 1,25 dihydroxyvitamin D , and/or cinacalcet duration study , except safety reason Willing able avoid antacid phosphate binder contain aluminum , magnesium , calcium lanthanum duration study unless prescribe even calcium supplement If female childbearing potential ( premenopausal surgically sterile ) , willing use effective contraceptive method throughout study , include barrier method , hormone , IUDs Expecting initiate dialysis duration study Considered compliant phosphate binder ( applicable ) Willing able provide inform consent Has participate investigational drug study within 30 day prior enrollment , Level understand willingness cooperate visit procedure describe study personnel Active bowel obstruction , dysphagia , swallow disorder severe gastrointestinal ( GI ) motility disorder Active ethanol drug abuse , exclude tobacco use Use antiarrhythmic antiseizure medication arrhythmia seizure disorder . In opinion investigator , patient poorly control diabetes mellitus , poorly control hypertension , active vasculitis , HIV infection , clinically significant unstable medical condition Pregnant breastfeeding Evidence active malignancy except basal cell carcinoma skin Unable comply requirement study Known hypersensitivity sevelamer constituent study drug Any condition , opinion investigator prohibit patient 's inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>